Clinical Gastroenterology and Hepatology

Article	Citations
Editorial Board	464
Front Cover	312
Hepatic Artery Pseudoaneurysm After Whipple Procedure	253
Table of Contents	246
Blue Notes	194
Fecal Microbiota Transplantation (FMT) in Ulcerative Colitis: Holding Out for a Superdonor?	188
Reply	177
Perianal Disease in Pediatric-onset Crohn’s Disease: Incidence, Disease Course, and Long-term Outcomes	176
Blue Notes	175
Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study	172
FODMAPs in IBS: Revisiting Restriction	169
Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial	157
Daily or Twice Daily Treatment With Topical Steroids Results in Similar Responses in Eosinophilic Esophagitis	156
An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States	155
Fibrosis-4 Index Predicts Long-Term All-Cause, Cardiovascular and Liver-Related Mortality in the Adult Korean Population	153
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA	152
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis	145
Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy	138
AGA Clinical Practice Update on Endoscopic Management of Perforations in Gastrointestinal Tract: Expert Review	133
Metabolic Signatures of Healthy Lifestyle Patterns and Colorectal Cancer Risk in a European Cohort	129
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary	127
Update in the Treatment of the Complications of Cirrhosis	126
AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review	120
Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study	119
Editorial Board	118

Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study	118
Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment	116
High Hospitalization Rates and Risk Factors Among Frail Patients With Cirrhosis: A 10-year Population-based Cohort Study	114
Elsewhere in the AGA Journals	112
Reply	109
Correction	108
Natural History of Patients Lost to Follow-up After Esophageal Food Impaction	106
Frequent Abnormal Pancreas Imaging in Patients With Pathogenic ATM, BRCA1, BRCA2, and PALB2 Breast Cancer Susceptibility Variants	104
Editorial Board	102
Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling	101
Look for a Physical Health Status Surrogate in Hepatocellular Carcinoma: Have we Found the Holy Grail?	100
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis	99
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease	98
Gut Microbiome Modulation by Antibiotics in Adult Asthma: A Human Proof-of-Concept Intervention Trial	98
Elsewhere in the AGA Journals	97
Reply	96
A Case of Pedunculated Esophageal Neuroendocrine Tumor G1	96
An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI	95
Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease	95
HBV RNA, Hepatitis B Core-Related Antigen, and Quantitative Hepatitis B Surface Antigen Biomarkers to Predict Outcome of Antiviral Therapy	94
The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy	93
The Evolving Landscape of Colorectal Cancer Screening and Colonoscopy Practice: Insights From the Japan Polyp Study	92
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials	91
A Novel, Noninvasive Method to Diagnose Active Eosinophilic Esophagitis, Combining Clinical Data and Oral Cavity RNA Levels	90
Gastric Emphysema With Hepatic Portal Venous Gas Secondary to Acute Gastric Mucosal Lesion	89
Endoscopic Polypectomy: How Should We Determine Complete Resection Status?	89
Overall and Annual Postcolonoscopy Colorectal Cancer Rates in a Large Integrated Healthcare Setting: A Cross-Sectional Study	89
An Unexpected Subepithelial Lesion: Catching the Diagnosis Earlier!	89
Issue Highlights	88
Reply	86
Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study	86
Attribution of Colonoscopy Risk Does Not FIT!	85
Aseptic Abscess Syndrome With Ulcerative Colitis and Pyoderma Gangrenosum	82
Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With CHB: A Comment for Moving Forward	79
Development of a Simple, Point-of-Care Device to Test Anorectal Function in Patients with Constipation: Randomized Clinical Trial	78
Relationship Between Gastric Emptying Rate and Simultaneously Assessed Symptoms in Functional Dyspepsia	76
Association of Statin Usage and the Development of Diabetes Mellitus after Acute Pancreatitis	76
Relative Cost-effectiveness of Management Strategies for Uninvestigated Dyspepsia	75
The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease	75
Disaggregating Racial and Ethnic Data: A Step Toward Diversity, Equity, and Inclusion	75
Low Daily Step Count Is Associated With a High Risk of Hospital Admission and Death in Community-Dwelling Patients With Cirrhosis	74
Fecal Immunochemical Tests: The Right Colorectal Cancer Screening Test for the Average-Risk Population?	73
Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability	73
Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States	71
Australasian Insights and Perspectives on the Burden of Chronic Liver Disease	71
Fecal Microbiota-based Therapies Compared to Fecal Microbiota Transplantation for Preventing Recurrent C. difficile Infection	70
Health Disparities in Inflammatory Bowel Disease Care Driven by Rural Versus Urban Residence: Challenges and Potential Solutions	70
Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial	70
Ambulatory Acute Kidney Injury in Patients With Cirrhosis Is Common and Burdensome	70
Barrett’s Esophagus Risk Factors in Patients Without Gastroesophageal Reflux: A Large Population-Based Study	69

Assessment and Significance of Histologic Activity in Crohn’s Disease	69
Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn’s Disease	69
PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission	69
National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States	68
In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent	68
Low Incidence of Pulmonary Aspiration During Upper Endoscopy in Patients Prescribed a Glucagon-Like Peptide 1 Receptor Agonist	68
Associations Between Sexual Orientation and Disorders of Gut-brain Interaction in Sexual Minority Populations	68
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn’s Disease: A Systematic Review and Meta-analysis	67
Prevalence of Gastric Precursor Lesions in Countries With Differential Gastric Cancer Burden: A Systematic Review and Meta-analysis	67
Table of Contents	67
AI-ASSISTED CAPSULE ENDOSCOPY FOR DETECTION OF ULCERS AND EROSIONS IN CROHN’S DISEASE: A MULTICENTER VALIDATION STUDY	67
Blue Notes	66
Front Cover	65
Editorial Board	65
Reply	65
Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges	64
Continuing the Commitment to Diversity, Equity, and Inclusion Within AGA Journals	64
Perianal Fistulizing Crohn’s Disease–Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus	64
Acute-onset Type 1 Diabetes Mellitus and Pancreatic Atrophy Caused by an Immune Checkpoint Inhibitor	64
Harm-to-Benefit Ratio of Fecal Immunochemical Test–Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations	63
Bouveret Syndrome Treated With Endoscopic Lithotripsy and Gallbladder Access via Cholecysto-duodenal Fistula	62
Response to “Recent Advancements and Future Perspectives of Per Oral Endoscopic Myotomy”	61
Extraintestinal Symptoms in Irritable Bowel Syndrome Are Associated With Stress Reactivity and the Gut Microbiome in a Sex-dependent Manner	61
The Affordable Care Act Improves Access, Survival, and Racial Disparities of Patients With Liver Disease: A Systematic Review	61
Risk of Advanced Colorectal Neoplasia at Follow-up Colonoscopy After Synchronous Adenoma and Clinically Significant Serrated Polyp	61
North American Expert Consensus on the Post-procedural Care of Patients After Per-oral Endoscopic Myotomy Using a Delphi Process	61
Reply	60
Real-world Comparison of Steatosis-Associated Fibrosis Estimator and Fibrosis-4 Scores for Assessing Metabolic Dysfunction-associated Steatotic Liver Disease-related Fibrosis in a Highly Diverse Urban	60
Low Colorectal Cancer Risk After Resection of High-Risk Pedunculated Polyps	59
An Unusual Complication of Endoscopic Ultrasound-guided Transgastric Liver Biopsy	59
Needle Track Seeding After Trans-gastric EUS-guided Tissue Sampling: Maybe Not as Rare as You Think	59
Assessing Diagnostic Performance of Modifications to the Rome IV Criteria for Irritable Bowel Syndrome	58
Environmental Toxins in Breast Milk and Risk of Early Onset Colorectal Cancer	58
Gastroparesis and Chronic Pancreatitis: Are They Truly Related?	58
Value of Ammonia Testing in Clinical Practice	57
Multiple Negative Fecal Immunochemical Tests: Is Testing Really Better?	57
Preoperative Hepatology and Primary Care Visits Improve Postoperative Outcomes in Patients With Cirrhosis Undergoing Surgery	57
Reply	57
Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network	57
Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations	56
The EXTENT Study: Results From an International Expert Delphi Consensus to Define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn’s Disease	56
Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma	56
Weight Change and the Development of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Overweight Individuals	56
All-cause and Cause-specific Mortality in Achalasia: A Nationwide Matched Cohort Study	56
Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies	56
Deficits in Geriatric Assessment Associate With Disease Activity and Burden in Older Patients With Inflammatory Bowel Disease	55
Distinctive Clinical Correlates of Small Intestinal Bacterial Overgrowth with Methanogens	55
Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis	54
Health Policy Priorities for the Biden Administration	53
Direct Oral Anticoagulants in Budd-Chiari Syndrome: Need a Closer Look!	53
The Severity of Reduced Esophageal Distensibility Parallels Eosinophilic Esophagitis Disease Duration	52
Constrictive and Hypertrophic Strictures in Ileal Crohn’s Disease	52
Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease	52
The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population	51
Colon Volume by Computed Tomography and Scintigraphic Colonic Transit in Constipated Patients With or Without Redundant Colon	51
Risk of Cancer in Biopsy-Proven Alcohol-Related Liver Disease: A Population-Based Cohort Study of 3410 Persons	51
Two vs One Forward View Examination of Right Colon on Adenoma Detection: An International Multicenter Randomized Trial	51
Distinct Clinical Physiologic Phenotypes of Patients With Laryngeal Symptoms Referred for Reflux Evaluation	51
Reply	50
Von Willebrand Factor Level Indicate Response to β-Blockers in Cirrhosis: Need a Closer Look!	50
Table of Contents	50
Editorial Board	50
Close Observation of the Lateral Walls of the Oropharynx During Esophagogastroduodenoscopy	50
Primary Sclerosing Cholangitis–Associated Pouchitis: A Distinct Clinical Phenotype	50
Reply	49
Unusual Presentation of a Crohn’s Disease Patient: Not Your Typical Flare	49
Information for Authors and Readers	49
Statins for Chronic Liver Disease and the Need for Randomized Controlled Trials	49
Reply	49
Hurdles in ERCP Trials: Do We Need to Change the Diagnostic Criteria for Post-ERCP Pancreatitis?	49
Editorial Board	49
Foaming at the Varix: Sclerotherapy of Esophageal Varices via Intrahepatic Portal Vein Access	48
Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey	48
Real-World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn’s Disease	48
Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion	48
Transient Uterine Prolapse: A Rare Complication of Endoscopic Polypectomy	47
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease	47
Reply	47
Cover	47
Reply	47

Cover	47
A Framework for Creating a FOAMed Organization in Gastroenterology: Lessons Learned from the Liver Fellow Network	47
Clinical Outcomes of Intraductal Papillary Mucinous Neoplasms With Dilatation of the Main Pancreatic Duct	47
Significance of Crypt Atypia in Barrett’s Esophagus: A Clinical, Molecular, and Outcome Study	46
Correction	46
The New Kids on the Block: Emerging Complementary Colonoscopy Quality Metrics	46
Population-based Screening for Hereditary Colorectal Cancer Variants in Japan	46
Uptake of Colorectal Cancer Screening in 45 to 49 Year Olds: An Early-Inning View from the Endoscopy Suite	46
Editorial Board	46
Diet and Microbiome-Directed Therapy 2.0 for IBD	45
Birth Cohort Colorectal Cancer (CRC): Implications for Research and Practice	45
Continuous Risk Score Predicts Waitlist and Post-transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes	45
Skills or Pills: Randomized Trial Comparing Hypnotherapy to Medical Treatment in Children With Functional Nausea	45
Upadacitinib in Mothers With Inflammatory Bowel Disease: Placental Transfer and Breast Milk Excretion	45
Prolonged Gastrointestinal Manifestations After Recovery From COVID-19	45
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis	45
Development of a Practical Guide to Implement and Monitor Diet Therapy for Eosinophilic Esophagitis	45
Exploring the Early Phase of Crohn’s Disease	45
A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis	44
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study	44
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis	44
Adenoma Detection Rate and Clinical Characteristics Influence Advanced Neoplasia Risk After Colorectal Polypectomy	44
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update	44
Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults	44
Editorial Board	43
Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control Subjects	43
Nonrecurrence Rate of Underwater EMR for ≤20-mm Nonampullary Duodenal Adenomas: A Multicenter Prospective Study (D-UEMR Study)	43
Front Cover	43
Reply	43
Diverticulosis Is Associated With Internal Hemorrhoids on Colonoscopy: Possible Clues to Etiology	43
Avoidant Restrictive Food Intake Disorder Prevalent Among Patients With Inflammatory Bowel Disease	43
Editorial Board	43
Reply	43
Nature and Nurture in Familial Aggregation of Steatotic Liver Disease	42
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis	42
Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic dysfunction–associated Steatotic Liver Disease in Clinical Practice	42
Defining Radiological Healing in Perianal Fistulizing Crohn’s Disease: a TOpClass Global Expert Delphi Consensus	42
Ustekinumab and Vedolizumab Safety and Clearance in Pregnancy With Inflammatory Bowel Disease: Stop the Disease, Not the Drug!	41
Diffuse Large B-Cell Duodenal Lymphoma Presenting With Obstruction and Pneumatosis	41
Reply	41
Interventional Radiological Management for Budd-Chiari Syndrome: A 10-Year Retrospective, Multicenter Survey on 997 Patients in China	41
Preparing the Next Generation of Gastroenterologists to Tackle Climate Change	41
Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study	41
Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-Analysis	41
AGA Clinical Practice Update on Endoscopic Lifting Agents: Commentary	41
Elsewhere in the AGA Journals	41
Prevalence of Liver Steatosis and Fibrosis in Adults With Primary Hypobetaliproteinemia: Results From the HYPOCHOL Study	41
Crafting a Therapeutic Pyramid for Eosinophilic Esophagitis in the Age of Biologics	41
Establishing an Endobariatric Practice: Steps, Challenges, and Considerations within a Private Practice Model	40
Prediction of Postoperative Recurrence in Crohn’s Disease: Where Do We Go From Here?	40
Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis	40
Reply	40
Letter Response to: Hernandez-Rocha C et al, Clin Gastroenterol Hepatol 2024	40
Endoscopic Sedation Type During FLIP Panometry Does Not Significantly Impact FLIP Motility Classification Relative to Manometry	40
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis	40
Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn’s Disease in the CELEST Extension Study	39
Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999–2018	39
Perceptions, Definitions, and Therapeutic Interventions for Occasional Constipation: A Rome Working Group Consensus Document	39
Effect of Exclusion Diets on Symptom Severity and the Gut Microbiota in Patients With Irritable Bowel Syndrome	39
Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis	39
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat	39
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study	38
Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension	38
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease	38
Patient Navigation Increases Linkage to Care and Receipt of Direct-acting Antiviral Therapy in Patients with Hepatitis C	38
Bleeding Gastric Teratoma on Adult Patient	38
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease	38
Reply	38
Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease	38
Reply	37
Lymphangioma in a Child Managed With Debulking Surgery	37
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases	37
To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn’s Disease	37
Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States	37
Approach to Dietary Restriction in Irritable Bowel Syndrome	37
Abdomino-anal Dyscoordination in Defecatory Disorders	37
Psychiatric Comorbidities Are Highly Prevalent in Nonesophageal Eosinophilic Gastrointestinal Diseases	37
Symptom Classes in Decompensated Liver Disease	36
Front Cover	36
Reply	36
Incomplete Response of Gastroesophageal Reflux Symptoms Poorly Predicts Erosive Esophagitis or Barrett’s Esophagus	36
Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy	36
Porcelain Gallbladder	36
Editorial Board	36
Hepatitis B RNA and Core-Related Antigen Provide Value Beyond DNA in Evaluating e But Not Surface Antigen Clearance	36
Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn’s Disease	36
Information for Authors and Readers	36
Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation	36
Disparities in Colorectal Cancer Screening Among Asian American Populations and Strategies to Address These Disparities	35
Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma With Varices Using Red Dichromatic Imaging	35
Dietary Fiber is Associated With Decreased Risk of Gastroesophageal Reflux Symptoms	35
Reply	35
Blue Notes	35
Elsewhere in the AGA Journals	35
Baseline Hepatitis B Virus Surface Antigen Titers in Childhood Predict the Risk of Advanced Liver Fibrosis in Adulthood	35